Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 7, 2008

Noxxon Receives $1.6M German Gov’t Grant to Accelerate Oligo Research

  • Noxxon was awarded a $1.6M (1M euro) research grant from Germany’s Federal Ministry of Education and Research. The funding was offered under the BioChancePlus initiative, a program that supports innovative research in biotechnology companies.

    The grant will be applied to strengthening and broadening the firm’s Spiegelmer® drug discovery platform to identify innovative medicines.

    A Spiegelmer® is a mirror-image oligonucleotide that can bind to a pharmacologically relevant target molecule in a manner conceptually similar to an antibody that recognizes an antigen, according to the company. The mirror image configuration of the oligonucleotide reportedly confers stability in all biological environments, as naturally occurring nucleases cannot degrade Spiegelmers.

     



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »